155 related articles for article (PubMed ID: 31247246)
1. Antivirals targeting the polymerase complex of influenza viruses.
Mifsud EJ; Hayden FG; Hurt AC
Antiviral Res; 2019 Sep; 169():104545. PubMed ID: 31247246
[TBL] [Abstract][Full Text] [Related]
2. Modeling mitigation of influenza epidemics by baloxavir.
Du Z; Nugent C; Galvani AP; Krug RM; Meyers LA
Nat Commun; 2020 Jun; 11(1):2750. PubMed ID: 32487990
[TBL] [Abstract][Full Text] [Related]
3. The impact of PA/I38 substitutions and PA polymorphisms on the susceptibility of zoonotic influenza A viruses to baloxavir.
Taniguchi K; Noshi T; Omoto S; Sato A; Shishido T; Matsuno K; Okamatsu M; Krauss S; Webby RJ; Sakoda Y; Kida H
Arch Virol; 2024 Jan; 169(2):29. PubMed ID: 38216710
[TBL] [Abstract][Full Text] [Related]
4. An orally active entry inhibitor of influenza A viruses protects mice and synergizes with oseltamivir and baloxavir marboxil.
Gaisina I; Li P; Du R; Cui Q; Dong M; Zhang C; Manicassamy B; Caffrey M; Moore T; Cooper L; Rong L
Sci Adv; 2024 Feb; 10(8):eadk9004. PubMed ID: 38394202
[TBL] [Abstract][Full Text] [Related]
5. Influenza antivirals and their role in pandemic preparedness.
Jones JC; Yen HL; Adams P; Armstrong K; Govorkova EA
Antiviral Res; 2023 Feb; 210():105499. PubMed ID: 36567025
[TBL] [Abstract][Full Text] [Related]
6. Influenza polymerase inhibitor resistance: Assessment of the current state of the art - A report of the isirv Antiviral group.
Ison MG; Hayden FG; Hay AJ; Gubareva LV; Govorkova EA; Takashita E; McKimm-Breschkin JL
Antiviral Res; 2021 Oct; 194():105158. PubMed ID: 34363859
[TBL] [Abstract][Full Text] [Related]
7. Newer influenza antivirals, biotherapeutics and combinations.
Hayden FG
Influenza Other Respir Viruses; 2013 Jan; 7 Suppl 1(Suppl 1):63-75. PubMed ID: 23279899
[TBL] [Abstract][Full Text] [Related]
8. Antiviral Susceptibilities of Distinct Lineages of Influenza C and D Viruses.
Takashita E; Murakami S; Matsuzaki Y; Fujisaki S; Morita H; Nagata S; Katayama M; Mizuta K; Nishimura H; Watanabe S; Horimoto T; Hasegawa H
Viruses; 2023 Jan; 15(1):. PubMed ID: 36680284
[TBL] [Abstract][Full Text] [Related]
9. Influenza Therapeutics in Clinical Practice-Challenges and Recent Advances.
Beigel JH; Hayden FG
Cold Spring Harb Perspect Med; 2021 Apr; 11(4):. PubMed ID: 32041763
[TBL] [Abstract][Full Text] [Related]
10. Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection.
Du YX; Chen XP
Clin Pharmacol Ther; 2020 Aug; 108(2):242-247. PubMed ID: 32246834
[TBL] [Abstract][Full Text] [Related]
11. Baloxavir marboxil: a novel cap-dependent endonuclease (CEN) inhibitor for the treatment of acute uncomplicated influenza.
Locke SC; Splawn LM; Cho JC
Drugs Today (Barc); 2019 Jun; 55(6):359-366. PubMed ID: 31250840
[TBL] [Abstract][Full Text] [Related]
12. Influenza and antiviral resistance: an overview.
Lampejo T
Eur J Clin Microbiol Infect Dis; 2020 Jul; 39(7):1201-1208. PubMed ID: 32056049
[TBL] [Abstract][Full Text] [Related]
13. Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial.
Lou Y; Liu L; Yao H; Hu X; Su J; Xu K; Luo R; Yang X; He L; Lu X; Zhao Q; Liang T; Qiu Y
Eur J Pharm Sci; 2021 Feb; 157():105631. PubMed ID: 33115675
[TBL] [Abstract][Full Text] [Related]
14. Influenza A variants with reduced susceptibility to baloxavir isolated from Japanese patients are fit and transmit through respiratory droplets.
Imai M; Yamashita M; Sakai-Tagawa Y; Iwatsuki-Horimoto K; Kiso M; Murakami J; Yasuhara A; Takada K; Ito M; Nakajima N; Takahashi K; Lopes TJS; Dutta J; Khan Z; Kriti D; van Bakel H; Tokita A; Hagiwara H; Izumida N; Kuroki H; Nishino T; Wada N; Koga M; Adachi E; Jubishi D; Hasegawa H; Kawaoka Y
Nat Microbiol; 2020 Jan; 5(1):27-33. PubMed ID: 31768027
[TBL] [Abstract][Full Text] [Related]
15. Novel influenza polymerase PB2 inhibitors for the treatment of influenza A infection.
Zhang H; Zhou L; Amichai S; Zandi K; Cox B; Schinazi R; Amblard F
Bioorg Med Chem Lett; 2019 Oct; 29(20):126639. PubMed ID: 31493987
[TBL] [Abstract][Full Text] [Related]
16. Susceptibility of Influenza A, B, C, and D Viruses to Baloxavir
Mishin VP; Patel MC; Chesnokov A; De La Cruz J; Nguyen HT; Lollis L; Hodges E; Jang Y; Barnes J; Uyeki T; Davis CT; Wentworth DE; Gubareva LV
Emerg Infect Dis; 2019 Oct; 25(10):1969-1972. PubMed ID: 31287050
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of a Cap-Dependent Endonuclease Inhibitor and Neuraminidase Inhibitors against H7N9 Highly Pathogenic Avian Influenza Virus Causing Severe Viral Pneumonia in Cynomolgus Macaques.
Suzuki S; Nguyen CT; Ogata-Nakahara A; Shibata A; Osaka H; Ishigaki H; Okamatsu M; Sakoda Y; Kida H; Ogasawara K; Itoh Y
Antimicrob Agents Chemother; 2021 Feb; 65(3):. PubMed ID: 33257455
[TBL] [Abstract][Full Text] [Related]
18.
Jeong JH; Choi WS; Antigua KJC; Choi YK; Govorkova EA; Webby RJ; Baek YH; Song MS
J Virol; 2020 Dec; 95(1):. PubMed ID: 33055248
[TBL] [Abstract][Full Text] [Related]
19. Favipiravir, an anti-influenza drug against life-threatening RNA virus infections.
Shiraki K; Daikoku T
Pharmacol Ther; 2020 May; 209():107512. PubMed ID: 32097670
[TBL] [Abstract][Full Text] [Related]
20. Insights into RNA-dependent RNA Polymerase Inhibitors as Antiinfluenza Virus Agents.
Giacchello I; Musumeci F; D'Agostino I; Greco C; Grossi G; Schenone S
Curr Med Chem; 2021; 28(6):1068-1090. PubMed ID: 31942843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
